[시장보고서]세계의 요실금 치료제 시장 - 규모, 점유율, 동향 분석 보고서 : 유형별, 약제 클래스별, 성별, 유통 채널별, 지역별, 부문 예측(2024-2030년)

세계의 요실금 치료제 시장 - 규모, 점유율, 동향 분석 보고서 : 유형별, 약제 클래스별, 성별, 유통 채널별, 지역별, 부문 예측(2024-2030년)

Urinary Incontinence Therapeutics Market Size, Share & Trends Analysis Report By Type (Stress, Urge, Overflow, Functional Incontinence), By Drug Class, By Gender, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

상품코드 : 1529818

리서치사 : Grand View Research

발행일 : 2024년 07월

페이지 정보 : 영문 150 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,830,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,315,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,283,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

시장 규모와 동향

요실금 치료제 세계 시장 규모는 2023년에 43억 7,000만 달러로 추정되며, 고령화 사회에서 요실금(UI) 유병률 증가와 이용 가능한 치료제법에 대한 인지도 증가 따라서 2024-2030년에 걸쳐 CAGR 4.0%로 확대될 것으로 예측되고 있습니다. Dovepress의 2023년 5월 보고서에 따르면 여성의 요실금 유병률은 24.8%로, 스트레스성 요실금은 12.7%로 가장 많았고, 혼합성 요실금은 8.0%, 절박성 요실금은 4.1%였습니다. 이 연구는 UI의 유병률이 연령과 체격 지수(BMI)와 함께 점차 증가하는 것을 강조했습니다.

이 시장에는 항콜린제, β3 아드레날린 작용제, 국소 에스트로겐 등 다양한 약물이 포함되어 있습니다. 이러한 약물은 방광 수축을 억제하고 방광 용량을 늘리고 요도와 질 조직을 강화하여 증상을 관리하는 데 도움이 됩니다. 시장 각 회사는 보다 효과적이고 안전한 치료제를 도입하기 위해 연구 개발에 지속적으로 투자하고 있으며, 이는 시장 성장을 가속하고 있습니다.

노화는 이 시장의 성장을 크게 뒷받침하고 있습니다. 세계의 평균 수명이 증가함에 따라 노인 수가 증가하고 UI를 포함한 노화 관련 질병의 유병률이 증가합니다. 고령자는 골반저근의 쇠퇴, 방광용량의 감소, 배뇨기능에 영향을 미치는 다른 건강상태에 의해 방광제어의 문제를 경험하는 경우가 많습니다. 이 인구 역학의 변화는 이러한 증상을 관리하고 완화하는 치료제 솔루션에 대한 수요 증가에 크게 기여합니다.

세계적으로 60세 이상의 인구는 2020년 10억명에서 2050년 21억명으로 두배로 늘어날 것으로 예측됩니다. 인구가 고령화됨에 따라 전복이나 섬망과 같은 UI 및 기타 노인 증후군의 부담이 증가할 것으로 예상됩니다. 이러한 증가는 보다 효과적이고 사용하기 쉬운 치료제를 필요로 하고, 이 부문의 연구개발을 추진하고 있습니다. 그 결과 의료 제공업체는 UI의 더 나은 관리를 통해 노인의 삶의 질을 향상시키는 데 주력하고 있습니다. 그 결과 시장이 확대되고 각 회사는 이러한 증가하는 환자 집단의 요구를 충족시키기 위해 혁신적인 치료제에 투자하고 있습니다.

또한, 의약품 개발의 진보도 이 시장의 성장에 크게 기여하고 있습니다. 연구자와 제약 회사는 더 나은 효능, 더 적은 부작용 및 향상된 전달 방법을 가진 신약의 개발에 주력하고 있습니다. 서방형 제제 및 병용 요법과 같은 기술 혁신으로 환자의 컴플라이언스와 치료제 성적이 향상되었습니다. 예를 들어, 2024년 4월, Lupin Ltd는 미국에서 과활동 방광 관리를 목적으로 하는 Myvetrick의 일반 대체품인 Mirabegron을 출시했습니다. 게다가, 새로운 약물 표적과 작용 메커니즘의 탐구는 보다 효과적인 치료제의 도입으로 이어집니다. 이러한 진보는 환자의 QOL을 향상시킬 뿐만 아니라 우수한 치료제 선택을 제공함으로써 시장 확대의 원동력이 되고 있습니다.

또한 최근 요실금에 대한 인식과 진단이 현저하게 높아지고 있습니다. 의료기관이나 제약회사의 건강캠페인과 교육 프로그램은 이 증상과 관련된 편견을 줄이고 의료기관과 상담하도록 촉구하는데 중요한 역할을 하고 있습니다. 또한 진단 도구와 진단 방법의 개선으로 의료 종사자가 요실금의 다양한 유형을 식별하고 분류하는 것이 용이해지고, 보다 개별화된 효과적인 치료제 계획이 세워지게 됩니다. 했습니다. 이러한 의식의 향상과 진단 능력의 향상으로 요실금 치료제의 환자층이 확대되고 있습니다.

요실금 치료제 세계 시장 세분화 보고서

이 보고서는 2018-2030년에 걸친 수익 성장을 국가 차원에서 예측하고 각 하위 부문에 대한 최신 산업 동향과 수익 기회에 대한 분석을 제공합니다. 이 조사 보고서는 세계 요실금 치료제 시장을 유형, 성별, 유통 채널, 약물 등급별, 지역별로 분류합니다.

요실금 치료제 시장 부문 대시보드
요실금 치료제 시장 : 약제 클래스별 변동 분석
약제 클래스별 요실금 치료제 시장 전망
2018-2030년 시장 규모와 예측과 동향 분석
항콜린제
베타 3 아드레날린 수용체 작용제
알파 차단제
에스트로겐
데스모프레신
삼환계 항우울제
기타

제6장 요실금 치료제 시장 : 유통 채널별, 추정·동향 분석

요실금 치료제 시장 부문 대시보드
요실금 치료제 시장 : 유통 채널별 변동 분석
유통 채널별 요실금 치료제 시장 전망
2018-2030년 시장 규모와 예측과 동향 분석
병원 약국
소매 약국
온라인 약국

제7장 요실금 치료제 시장 : 성별, 추정·동향 분석

요실금 치료제 시장 부문 대시보드
요실금 치료제 시장 : 성별 변동 분석
성별 요실금 치료제 시장 전망
2018-2030년 시장 규모와 예측과 동향 분석
남성
여성

제8장 요실금 치료제 시장 :지역별, 추정·동향 분석

지역 대시보드
시장 규모, 예측 동향 분석, 2018-2030년
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 스웨덴
- 덴마크
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제9장 경쟁 구도

시장 진출기업의 분류
주요 기업 프로파일
- Pfizer Inc.
- AbbVie Inc.
- Astellas Pharma Inc.
- Johnson &Johnson
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Sanofi SA
- GlaxoSmithKline plc
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Bayer AG
- Ferring Pharmaceuticals

JHS

영문 목차

영문목차

Market Size & Trends

The global urinary incontinence therapeutics market size was estimated at USD 4.37 billion in 2023 and is projected to expand at a CAGR of 4.0% from 2024 to 2030 due to the increasing prevalence of urinary incontinence (UI) among aging populations and the rising awareness about available treatments. According to a May 2023 report by Dovepress, the prevalence of female UI was found to be 24.8%, with stress UI being the most common subtype at 12.7%, followed by mixed UI at 8.0%, and urgency UI at 4.1%. The study highlighted that the prevalence of UI increased progressively with age and body mass index (BMI).

This market includes a variety of medications such as anticholinergics, beta-3 adrenergic agonists, and topical estrogens. These drugs help manage symptoms by reducing bladder contractions, increasing bladder capacity, and strengthening urethral and vaginal tissues. Market players are continuously investing in research and development to introduce more effective and safer treatments, which is propelling market growth.

The aging population is majorly driving the growth of this market. As global life expectancy increases, the number of elderly individuals is rising, leading to a higher prevalence of age-related conditions, including UI. Older adults often experience bladder control issues due to weakened pelvic floor muscles, decreased bladder capacity, and other health conditions that impact urinary function. This demographic shift significantly contributes to the growing demand for therapeutic solutions to manage and alleviate these symptoms.

Globally, the number of people aged 60 and older is projected to double from 1 billion in 2020 to 2.1 billion by 2050. As the population ages, the burden of UI and other geriatric syndromes like falls and delirium is expected to grow. This increase necessitates more effective and accessible treatments, driving research and development in this sector. Consequently, healthcare providers are focusing on improving the quality of life for older adults through better management of UI. As a result, the market is expanding, with companies investing in innovative treatments to meet the needs of this growing patient population.

In addition, advancements in drug development are significantly contributing to the growth of this market. Researchers and pharmaceutical companies are focusing on developing new drugs with better efficacy, fewer side effects, and improved delivery methods. Innovations such as extended-release formulations and combination therapies are enhancing patient compliance and treatment outcomes. For instance, in April 2024, Lupin Ltd introduced Mirabegron, a generic alternative to Mybetriq, aimed at managing overactive bladder in the U.S. Additionally, the exploration of novel drug targets and mechanisms of action is leading to the introduction of more effective therapies. These advancements not only improve the quality of life for patients but also drive market expansion by offering superior treatment options.

Furthermore, there has been a notable increase in awareness and diagnosis of urinary incontinence in recent years. Health campaigns and educational programs by healthcare organizations and pharmaceutical companies have played a crucial role in reducing the stigma associated with this condition and encouraging individuals to seek medical advice. Improved diagnostic tools and methods have also made it easier for healthcare providers to identify and classify different types of urinary incontinence, leading to more personalized and effective treatment plans. This heightened awareness and better diagnostic capabilities are expanding the patient base for UI therapeutics.

Global Urinary Incontinence Therapeutics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global urinary incontinence therapeutics market report based on type, gender, distribution channel, drug class, and region.

Type Outlook (Revenue, USD Billion; 2018 - 2030)
Stress Incontinence
Urge Incontinence
Overflow Incontinence
Functional Incontinence
Other Types
Drug Class Outlook (Revenue, USD Billion; 2018 - 2030)
Anticholinergics
Beta-3 Adrenoceptor Agonists
Alpha Blockers
Estrogen
Desmopressin
Tricyclic Antidepressants
Other Drug Classes
Gender Outlook (Revenue, USD Billion; 2018 - 2030)
Male
Female
Distribution Channel Outlook (Revenue, USD Billion; 2018 - 2030)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Outlook (Revenue, USD Billion; 2018 - 2030)
North America

U.S.

Canada

Mexico

Europe

Germany

France

Italy

Spain

Norway

Denmark

Sweden

Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

Latin America

Brazil

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Age
- 1.2.3. Distribution Channel
- 1.2.4. Drug Class
- 1.2.5. Regional Scope
- 1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Type outlook
- 2.2.2. Age outlook
- 2.2.3. Distribution channel outlook
- 2.2.4. Drug class outlook
2.3. Regional outlook
2.4. Competitive Insights

Chapter 3. Urinary Incontinence Therapeutics Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Urinary Incontinence Therapeutics Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's Five Forces
  - 3.3.1.1. Bargaining power of suppliers
  - 3.3.1.2. Bargaining power of buyers
  - 3.3.1.3. Threat of substitutes
  - 3.3.1.4. Threat of new entrants
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Economic landscape
  - 3.3.2.3. Social landscape
  - 3.3.2.4. Technological landscape
  - 3.3.2.5. Environmental landscape
  - 3.3.2.6. Legal landscape
- 3.3.3. Pipeline Analysis

Chapter 4. Urinary Incontinence Therapeutics Market: Type Estimates & Trend Analysis

4.1. Urinary Incontinence Therapeutics Market Segment Dashboard
4.2. Urinary Incontinence Therapeutics Market: Type Movement Analysis
4.3. Urinary Incontinence Therapeutics Market by Type Outlook (USD Billion)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Stress Incontinence
- 4.5.1. Stress Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.6. Urge Incontinence
- 4.6.1. Urge Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.7. Overflow Incontinence
- 4.7.1. Overflow Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.8. Functional Incontinence
- 4.8.1. Functional Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.9. Others
- 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Urinary Incontinence Therapeutics Market: Drug Class Estimates & Trend Analysis

5.1. Urinary Incontinence Therapeutics Market Segment Dashboard
5.2. Urinary Incontinence Therapeutics Market: Drug Class Movement Analysis
5.3. Urinary Incontinence Therapeutics Market by Drug Class Outlook (USD Billion)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Anticholinergics
- 5.5.1. Anticholinergics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6. Beta-3 Adrenoceptor Agonists
- 5.6.1. Beta-3 Adrenoceptor Agonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.7. Alpha Blockers
- 5.7.1. Alpha Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.8. Estrogen
- 5.8.1. Estrogen Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.9. Desmopressin
- 5.9.1. Desmopressin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.10. Tricyclic Antidepressants
- 5.10.1. Tricyclic Antidepressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.11. Others
- 5.11.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Urinary Incontinence Therapeutics Market: Distribution Channel Estimates & Trend Analysis

6.1. Urinary Incontinence Therapeutics Market Segment Dashboard
6.2. Urinary Incontinence Therapeutics Market: Distribution Channel Movement Analysis
6.3. Urinary Incontinence Therapeutics Market by Distribution Channel Outlook (USD Billion)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. Hospital Pharmacies
- 6.5.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6. Retail Pharmacies
- 6.6.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.7. Online Pharmacies
- 6.7.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Urinary Incontinence Therapeutics Market: Gender Estimates & Trend Analysis

7.1. Urinary Incontinence Therapeutics Market Segment Dashboard
7.2. Urinary Incontinence Therapeutics Market: Gender Movement Analysis
7.3. Urinary Incontinence Therapeutics Market by Gender Outlook (USD Billion)
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.5. Male
- 7.5.1. Male Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6. Female
- 7.6.1. Female Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Urinary Incontinence Therapeutics Market: Regional Estimates & Trend Analysis

8.1. Regional Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.3. North America
- 8.3.1. U.S.
  - 8.3.1.1. Key country dynamics
  - 8.3.1.2. Regulatory framework/ reimbursement structure
  - 8.3.1.3. Competitive scenario
  - 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
- 8.3.2. Canada
  - 8.3.2.1. Key country dynamics
  - 8.3.2.2. Regulatory framework/ reimbursement structure
  - 8.3.2.3. Competitive scenario
  - 8.3.2.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
- 8.3.3. Mexico
  - 8.3.3.1. Key country dynamics
  - 8.3.3.2. Regulatory framework/ reimbursement structure
  - 8.3.3.3. Competitive scenario
  - 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
8.4. Europe
- 8.4.1. UK
  - 8.4.1.1. Key country dynamics
  - 8.4.1.2. Regulatory framework/ reimbursement structure
  - 8.4.1.3. Competitive scenario
  - 8.4.1.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
- 8.4.2. Germany
  - 8.4.2.1. Key country dynamics
  - 8.4.2.2. Regulatory framework/ reimbursement structure
  - 8.4.2.3. Competitive scenario
  - 8.4.2.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
- 8.4.3. France
  - 8.4.3.1. Key country dynamics
  - 8.4.3.2. Regulatory framework/ reimbursement structure
  - 8.4.3.3. Competitive scenario
  - 8.4.3.4. France market estimates and forecasts 2018 to 2030, (USD Million)
- 8.4.4. Italy
  - 8.4.4.1. Key country dynamics
  - 8.4.4.2. Regulatory framework/ reimbursement structure
  - 8.4.4.3. Competitive scenario
  - 8.4.4.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
- 8.4.5. Spain
  - 8.4.5.1. Key country dynamics
  - 8.4.5.2. Regulatory framework/ reimbursement structure
  - 8.4.5.3. Competitive scenario
  - 8.4.5.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
- 8.4.6. Norway
  - 8.4.6.1. Key country dynamics
  - 8.4.6.2. Regulatory framework/ reimbursement structure
  - 8.4.6.3. Competitive scenario
  - 8.4.6.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
- 8.4.7. Sweden
  - 8.4.7.1. Key country dynamics
  - 8.4.7.2. Regulatory framework/ reimbursement structure
  - 8.4.7.3. Competitive scenario
  - 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
- 8.4.8. Denmark
  - 8.4.8.1. Key country dynamics
  - 8.4.8.2. Regulatory framework/ reimbursement structure
  - 8.4.8.3. Competitive scenario
  - 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
8.5. Asia Pacific
- 8.5.1. Japan
  - 8.5.1.1. Key country dynamics
  - 8.5.1.2. Regulatory framework/ reimbursement structure
  - 8.5.1.3. Competitive scenario
  - 8.5.1.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
- 8.5.2. China
  - 8.5.2.1. Key country dynamics
  - 8.5.2.2. Regulatory framework/ reimbursement structure
  - 8.5.2.3. Competitive scenario
  - 8.5.2.4. China market estimates and forecasts 2018 to 2030, (USD Million)
- 8.5.3. India
  - 8.5.3.1. Key country dynamics
  - 8.5.3.2. Regulatory framework/ reimbursement structure
  - 8.5.3.3. Competitive scenario
  - 8.5.3.4. India market estimates and forecasts 2018 to 2030, (USD Million)
- 8.5.4. Australia
  - 8.5.4.1. Key country dynamics
  - 8.5.4.2. Regulatory framework/ reimbursement structure
  - 8.5.4.3. Competitive scenario
  - 8.5.4.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
- 8.5.5. South Korea
  - 8.5.5.1. Key country dynamics
  - 8.5.5.2. Regulatory framework/ reimbursement structure
  - 8.5.5.3. Competitive scenario
  - 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
- 8.5.6. Thailand
  - 8.5.6.1. Key country dynamics
  - 8.5.6.2. Regulatory framework/ reimbursement structure
  - 8.5.6.3. Competitive scenario
  - 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
8.6. Latin America
- 8.6.1. Brazil
  - 8.6.1.1. Key country dynamics
  - 8.6.1.2. Regulatory framework/ reimbursement structure
  - 8.6.1.3. Competitive scenario
  - 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
- 8.6.2. Argentina
  - 8.6.2.1. Key country dynamics
  - 8.6.2.2. Regulatory framework/ reimbursement structure
  - 8.6.2.3. Competitive scenario
  - 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
8.7. MEA
- 8.7.1. South Africa
  - 8.7.1.1. Key country dynamics
  - 8.7.1.2. Regulatory framework/ reimbursement structure
  - 8.7.1.3. Competitive scenario
  - 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
- 8.7.2. Saudi Arabia
  - 8.7.2.1. Key country dynamics
  - 8.7.2.2. Regulatory framework/ reimbursement structure
  - 8.7.2.3. Competitive scenario
  - 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
- 8.7.3. UAE
  - 8.7.3.1. Key country dynamics
  - 8.7.3.2. Regulatory framework/ reimbursement structure
  - 8.7.3.3. Competitive scenario
  - 8.7.3.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
- 8.7.4. Kuwait
  - 8.7.4.1. Key country dynamics
  - 8.7.4.2. Regulatory framework/ reimbursement structure
  - 8.7.4.3. Competitive scenario
  - 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 9. Competitive Landscape

9.1. Market Participant Categorization
9.2. Key Company Profiles
- 9.2.1. Pfizer Inc.
  - 9.2.1.1. Company overview
  - 9.2.1.2. Financial performance
  - 9.2.1.3. Age benchmarking
  - 9.2.1.4. Strategic initiatives
- 9.2.2. AbbVie Inc.
  - 9.2.2.1. Company overview
  - 9.2.2.2. Financial performance
  - 9.2.2.3. Age benchmarking
  - 9.2.2.4. Strategic initiatives
- 9.2.3. Astellas Pharma Inc.
  - 9.2.3.1. Company overview
  - 9.2.3.2. Financial performance
  - 9.2.3.3. Age benchmarking
  - 9.2.3.4. Strategic initiatives
- 9.2.4. Johnson & Johnson
  - 9.2.4.1. Company overview
  - 9.2.4.2. Financial performance
  - 9.2.4.3. Age benchmarking
  - 9.2.4.4. Strategic initiatives
- 9.2.5. Viatris Inc.
  - 9.2.5.1. Company overview
  - 9.2.5.2. Financial performance
  - 9.2.5.3. Age benchmarking
  - 9.2.5.4. Strategic initiatives
- 9.2.6. Teva Pharmaceutical Industries Ltd.
  - 9.2.6.1. Company overview
  - 9.2.6.2. Financial performance
  - 9.2.6.3. Age benchmarking
  - 9.2.6.4. Strategic initiatives
- 9.2.7. Sanofi S.A.
  - 9.2.7.1. Company overview
  - 9.2.7.2. Financial performance
  - 9.2.7.3. Age benchmarking
  - 9.2.7.4. Strategic initiatives
- 9.2.8. GlaxoSmithKline plc
  - 9.2.8.1. Company overview
  - 9.2.8.2. Financial performance
  - 9.2.8.3. Age benchmarking
  - 9.2.8.4. Strategic initiatives
- 9.2.9. Boehringer Ingelheim Pharmaceuticals, Inc.
  - 9.2.9.1. Company overview
  - 9.2.9.2. Financial performance
  - 9.2.9.3. Age benchmarking
  - 9.2.9.4. Strategic initiatives
  - 9.2.9.5. Strategic initiatives
  - 9.2.9.6. Strategic initiatives
- 9.2.10. Bayer AG
  - 9.2.10.1. Company overview
  - 9.2.10.2. Financial performance
  - 9.2.10.3. Age benchmarking
  - 9.2.10.4. Strategic initiatives
  - 9.2.10.5. Strategic initiatives
- 9.2.11. Ferring Pharmaceuticals
  - 9.2.11.1. Company overview
  - 9.2.11.2. Financial performance
  - 9.2.11.3. Age benchmarking
  - 9.2.11.4. Strategic initiatives
  - 9.2.11.5. Strategic initiatives